CVS Health Co. (NYSE:CVS) Shares Sold by Capital Research Global Investors

Capital Research Global Investors decreased its holdings in CVS Health Co. (NYSE:CVS - Free Report) by 55.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,505,406 shares of the pharmacy operator's stock after selling 3,138,879 shares during the period. Capital Research Global Investors owned 0.20% of CVS Health worth $112,468,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. EagleClaw Capital Managment LLC increased its stake in CVS Health by 3.4% in the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock worth $275,000 after buying an additional 200 shares during the period. Manchester Capital Management LLC increased its position in CVS Health by 4.8% during the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock valued at $200,000 after buying an additional 204 shares in the last quarter. Angeles Investment Advisors LLC boosted its stake in CVS Health by 3.7% in the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock worth $256,000 after purchasing an additional 204 shares in the last quarter. Rogco LP raised its stake in CVS Health by 3.2% in the 4th quarter. Rogco LP now owns 6,752 shares of the pharmacy operator's stock worth $303,000 after acquiring an additional 210 shares during the last quarter. Finally, Cozad Asset Management Inc. raised its position in CVS Health by 3.7% during the 4th quarter. Cozad Asset Management Inc. now owns 6,532 shares of the pharmacy operator's stock worth $293,000 after buying an additional 233 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CVS Health

In other news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael F. Mahoney bought 30,000 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now directly owns 39,356 shares of the company's stock, valued at $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on CVS shares. Barclays increased their price target on shares of CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Mizuho boosted their price objective on CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. UBS Group cut their price target on shares of CVS Health from $62.00 to $59.00 and set a "neutral" rating for the company in a report on Tuesday, February 11th. StockNews.com raised shares of CVS Health from a "sell" rating to a "hold" rating in a report on Thursday, February 13th. Finally, Cantor Fitzgerald raised CVS Health from a "neutral" rating to an "overweight" rating in a report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and an average price target of $71.83.

CVS Health Trading Down 0.9 %

Shares of CVS traded down $0.62 during trading on Friday, reaching $65.30. 5,019,853 shares of the company traded hands, compared to its average volume of 11,808,414. The stock has a 50-day simple moving average of $66.49 and a 200-day simple moving average of $58.87. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $71.45. The stock has a market cap of $82.33 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.07%. CVS Health's dividend payout ratio (DPR) is presently 72.68%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.